Cite
HARVARD Citation
Mo, D. et al. (2022). Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer. Journal of clinical oncology. 40 (5), pp. 522-523. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Mo, D. et al. (2022). Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer. Journal of clinical oncology. 40 (5), pp. 522-523. [Online].